Skip to search formSkip to main contentSkip to account menu

THERATOPE

Known as: THERATOPE STn-KLH vaccine 
National Institutes of Health

Related topics

Related topics

2 relations
cyclophosphamide/THERATOPE STn-KLH vaccinesialyl-Tn antigen-keyhole-limpet hemocyanin conjugate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2004
Review
2004
Vaccination with Theratope® (STn-KLH) as treatment for breast cancer
Cancer vaccines have demonstrated that they can stimulate antibody and cell-mediated immune responses against tumor-associated… 
Review
2003
Review
2003
Clinical development of the STn-KLH vaccine (Theratope).
The development of active specific immunotherapy depends on the identification of altered cancer cell-specific molecules or… 
Review
2003
Review
2003
Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer.
Mucin-1 (MUC-1) is a high-molecular-weight glycoprotein rich in serine and threonine residues that are O-glycosylated. Expression… 
2003
2003
The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope).
The success of high-dose chemotherapy followed by autologous stem-cell rescue as treatment for breast and ovarian cancer is… 
Review
2003
Review
2003
Cancer Vaccine THERATOPE® — Biomira
Biomira is developing a therapeutic cancer vaccine [THERATOPE®] for treatment of breast and other cancers.1 THERATOPE® consists… 
Review
2001
Review
2001
Theratope® vaccine (STn-KLH)
Active specific immunotherapy (ASI) is a promising approach to treating cancer. Numerous studies in the laboratory have… 
Highly Cited
2000
Highly Cited
2000
Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE® STn-KLH cancer vaccine
The purpose of this study was to evaluate the toxicity and potential efficacy of administering the THERATOPE® STn-KLH cancer… 
Review
2000
Review
2000
Technology evaluation: Theratope, Biomira Inc.
  • M. Morse
  • Current opinion in molecular therapeutics (Print)
  • 2000
  • Corpus ID: 39168794
Active specific immunotherapy, the use of 'vaccines' to stimulate therapeutic tumor antigen-specific immune responses, holds… 
Highly Cited
1996
Highly Cited
1996
Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide.
THERATOPE (Biomira Inc., Edmonton, AB, Canada) STn-KLH cancer vaccine induces strong antibody titers against both the synthetic… 
Highly Cited
1996
Highly Cited
1996
Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope® sialyl-Tn-KLH cancer vaccine in active specific immunotherapy
Abstract Patients with metastatic breast, colorectal or ovarian cancers received active specific immunotherapy (ASI) with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)